Section Arrow
DNLI.NASDAQ
- Denali Therapeutics
Quotes are at least 15-min delayed:2025/07/21 07:00 EDT
Pre Market
Last
 14.2
+0.2 (+1.43%)
Bid
14
Ask
15.97
High 14.2 
Low 14.17 
Volume 75 
Regular Hours
Last
 14
-0.53 (-3.65%)
Day High 
14.845 
Prev. Close
14.53 
1-M High
15.375 
Volume 
1.31M 
Bid
14
Ask
15.97
Day Low
13.96 
Open
14.74 
1-M Low
13.41 
Market Cap 
2.11B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 14.64 
20-SMA 14.41 
50-SMA 14.26 
52-W High 33.33 
52-W Low 10.57 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.67/-2.02
Enterprise Value
2.15B
Balance Sheet
Book Value Per Share
7.73
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
2.35
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
Pre Market 2 -0.28 -12.28%
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
Pre Market 13.05 -1.025 -7.28%
NCNANuCana plc0.0477+0.0009+1.92%-- 
Pre Market 0.0479 +0.0002 +0.42%
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
Pre Market 6.16 +0.32 +5.48%
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Pre Market 6.19 +0.27 +4.56%
Quotes are at least 15-min delayed:2025/07/21 07:00 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brainpenetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.